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Abbreviations 
AJCC  American Joint Cancer Committee 
CgA  Chromogranin A 
CI  confidence interval 
CT  computed tomography  
ENETS European Neuroendocrine Tumor Society 
EUS  endoscopic ultrasonography  
FNA  fine-needle aspiration 
f-pNET functional pancreatic neuroendocrine tumor 
ISGPS  International Study Group of Pancreatic Surgery 
MEN-1  Multiple Endocrine Neoplasia-type 1 
MRI  magnetic resonance imaging 
mTOR  mammalian target of rapamycin 
NF-1  Neurofibromatosis type 1 
nf-pNET non-functional pancreatic neuroendocrine tumor 
PET  positron-emission tomographic 
PFS  progression-free survival 
pNET  pancreatic neuroendocrine tumor 
PPI  proton pump inhibitor 
PPPD  pylorus-preserving pancreaticoduodenectomy 
RFA  radio frequency ablation 
SIRT  selective internal radiation therapy 
SPECT single-photon emission computed tomography 
SRS  somatostatin receptor scanning 
sst  somatostatin receptor subtype 
TACE  transarterial chemoembolization 
TNM  tumor-node-metastasis 
UICC  Union for International Cancer Control 
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1 Introduction 
1.1  Nomenclature 
Neuroendocrine tumors can arise from neuroendocrine cells throughout the body. Some of 
the tumors are able to produce peptides and hormones and cause characteristic symptoms 
(i.e. hypoglycemia, watery diarrhea). Others lack characteristic symptoms and get clinically 
apparent due to tumor mass effects (i.e. jaundice, abdominal pain, pancreatitis) 1. In 1907 the 
German pathologist Siegfried Oberndorfer, who called them carcinoids, described these 
tumors for the first time 2. Many years later the World Health Organization (WHO) introduced 
the term “neuroendocrine neoplasm” to accentuate the potential malignant behavior 3.  
In 2006, the European Neuroendocrine Tumor Society (ENETS) introduced its own grading 
system 4. The nuclear mitosis rate and the Ki-67 index are important components in the 
ENETS classification and in 2012 the first revision of the ENETS guidelines was published 5, 
6. 
Besides the efforts of the ENETS, the International Union for Cancer Control (UICC) also 
released a TNM staging system, which is accompanied by both the American Joint Cancer 
Committee (AJCC) and the WHO 7-9. Due to the fact, that the UICC/AJCC/WHO 2010 TNM is 
the same as for ductal adenocarcinoma, it was adapted and validated recently 10. The 
differences of the two systems will be highlighted in the following sections. 
 
 
1.2 Epidemiology 
pNETs are a diverse group of rare neoplasms and divided into two main groups, functional  
(f-pNET) and non-functional tumors (nf-pNET). The annual pNET incidence is 0,3 – 0,4 per 
100 000 in the United States 11, 1,01 per 100 000 in Japan 12. Interestingly, autopsy studies 
reported on an incidence of 10 % 13. Beyond controversy the incidence has risen in the past 
decades, which might be due to a true change in disease or better disease detection.  
nf-pNETs are twice as frequent as f-pNETs 14. Data about functional pNETs vary in different 
publications, but the results indicate that insulinomas are the most frequent f-pNETs, 
followed by gastrinomas, glucagonomas, VIPomas, somatostatinomas and others 15, 16.  
Most pNETs are sporadic, although, there are four inherited disorders, which are associated 
with a high incidence of pNETs in younger patients. The most common of these four is called 
Multiple Endocrine Neoplasia-type 1 (MEN-1). Patients suffering from MEN-1 will develop in 
80 – 100 % nf-pNETs, in 50 – 60 % gastrinomas, in 20 % insulinomas and in 3 – 5 % 
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VIPomas or glucagonomas 17, 18. Death at younger ages in MEN-1 patients is often because 
of pNETs 19. Moreover, it is reported that the MEN-1 population account for 20 – 25 % of all 
gastrinomas, for 4 % of all insulinomas and for almost 8 % of all nf-pNETs 17, 20, 21. 
Furthermore, there is von Hippel-Lindau disease (VHL), which is associated with a broad 
spectrum of pancreatic lesions. These patients mainly develop true pancreatic cysts (91 %), 
whereas a minority of 10 – 17 % has pNETs (primarily nf-pNET) 22.  
Patients suffering from Neurofibromatosis type 1 (NF-1) (von Recklingshausen’s disease) 
show in up to 10 % pNETs, whereas pNETs are even more infrequent in tuberous sclerosis 
patients (< 1 %) 18.   
 
 
1.3 Pathogenesis 
pNETs arise from neuroendocrine cells with both neural and endocrine characteristics. 
Historically it was believed that pNETs originate from the islets of Langerhans, but more 
recent studies revealed that pluripotent stem cells give rise to pNETs 23. Hence, these tumors 
secrete typical substances, such as pancreatic polypeptide, Chromogranin A, synaptophysin 
or neuronspecific enolase 24, 25. The sequence from a regular stem cell to a neuroendocrine 
tumor is still not understood. Nevertheless, specific gene mutations are frequently detected in 
pNET (MEN1, DAXX, ATRX and mTOR) 26. Although, an alteration in most common 
oncogenes (fos, jun, myc, k-ras) or tumor suppressor genes (p53, retinoblastoma) is not 
often detected 27, 28.   
 
 
1.4 Diagnosis 
The diagnosis of f-pNETs is confirmed as a result of symptoms caused by the secreted 
hormones and subsequent biochemical testing. Nevertheless imaging studies are essential 
to distinguish primary tumor localization and the extent of disease to define if curative 
resection is possible or just cytoreductive surgery. pNETs are typically hypervascularized 
and therefore visualized in the early arterial phase of imaging. Moreover, imaging is 
indispensable to monitor patients after antitumor treatment. Biomarker profiles for patients 
suffering from a pNET are not as valid as for other solid tumors.  
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1.4.1  Conventional cross-sectional imaging 
Contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) are 
available in almost every clinic and as a consequence generally used to detect a pNET. 
ENETS demands a contrast-enhanced multidetector CT scan with slices < 1 mm at specified 
time points (arterial, portal-venous and late venous phase) 5. Dependent on tumor size a 
sensitivity and specificity of a CT scan of 73 and 96 % is reached 29.  
Since next generation contrast mediums and better MRI detectors are available this modality 
is also widely used. The tumors are well visualized in fat-suppressed T1-weighted images 
and combined with T2-weighted images a more subtle differentiation of the pancreatic tumor 
is feasible. MRI is mainly utilized for the detection and further distinction of liver tumors.  
Taken together CT and MRI reach a sensitivity of 55 – 78 % for detecting the primary 
pancreatic tumor, however, are highly sensitive (94%) in tracing liver metastases. CT and 
MRI especially lose ground if the primary pancreatic tumor is smaller than 1 cm 30.  
 
1.4.2 Endoscopic ultrasonography 
Endoscopic ultrasonography (EUS) is commonly used especially for very small tumors (< 1 
cm). Moreover EUS can be combined with fine-needle aspiration (FNA) to distinguish 
between a nf-pNET and an adenocarcinoma or some other pancreatic tumor mass. In MEN-
1 patients EUS plays an important role in identifying small pNETs since these patients suffer 
from nf-pNETs in 80 – 100 % 31. EUS/FNA is rarely needed in f-pNETs because they are 
diagnosed by biochemical testing. A domain for EUS is the localization of small insulinomas, 
which are very small, intrapancreatic and not seen with conventional imaging methods and 
scintigraphy 32, 33. 
However, EUS/FNA is highly operator-dependent, cannot accurately identify liver metastases 
and is more effective in localizing intrapancreatic than extrapancreatic masses, such as 
duodenal gastrinomas 34, 35.  
 
1.4.3 Nuclear imaging 
pNETs frequently (> 80 %) show high density of somatostatin receptor subtypes (sst), 
particularly sst 2 and sst 5 36. These receptors have a high affinity for synthetic somatostatin 
analogues, like octreotide and lanreotide, whereupon only octreotide is approved for patient 
use in the United States and is worldwide the most common applied agent for somatostatin 
receptor scanning (SRS or Octreoscan). For SRS radiolabeled octreotide (111-In-DTPA-
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octreotide) is used to detect pNETs and SRS is capable to identify 50 – 70 % of primary 
pNETs, although less than 25 % of insulinomas will be found because these tumors express 
only few sst 2 and sst 5 37, 38. This might also be due to the fact that insulinomas are often 
small and the sensitivity to identify tumors < 1 cm averages only 50 % 39. SRS facilitates 
entire body scans and as a consequence distant metastases (i.e. liver, bone, lung) are 
identified quickly. Hence, studies have proven that the therapy strategy of patients with 
pNETs has changed because of SRS findings in 24 – 47 %. When SRS is combined with CT 
a sensitivity of 90 % and a specifity of 80 % is reached 39, 40. False positive results occur in up 
to 12 % of patients mainly because of thyroid disease, breast disease, lymphoma or 
cholangiocarcinoma, nonetheless this rate can be minimized to 3 % if the findings are 
interpreted accurately within the clinical context 17, 40.  
To detect pNETs positron-emission tomographic (PET) scanning was also tested, but this 
imaging method achieved inferior results. Responsible for this circumstance is the fact that 
pNETs have a slow glucose turnover 36. The contemporary standard of SRS imaging 
represents the fusion of SRS with single-photon emission computed tomography (SPECT) 
and is available at almost every center. 
“Next generation” in pNET-imaging represents 68Gallium-DOTA-[Tyr3]octreotide (Ga-DOTA-
TATE)-PET or 68Gallium-DOTA-[Tyr3]octreotide (Ga-DOTA-TOC)-PET, however, these 
methods are available only in selected centers. With this scanning method, which features 
complete staging with one examination, the sensitivity is increased up to 97 % and an 
accuracy of 96 % is reached 41.  
 
1.4.4 Biochemical assessment and functional localization 
Since functional pNETs secrete a specific hormone, this hormone should be measured to 
establish the diagnosis. For insulinoma, it is recommended to assess serum levels of 
glucose, insulin, proinsulin and C-peptide during a fast 42.  
On the other hand the majority of pNETs are non functional and not associated with a clinical 
hormone syndrome. Nevertheless, nf-pNETs secrete measurable levels of amines and 
peptides.  
Chromogranin A (CgA) is the most commonly secreted, by both f-pNET and nf-pNET, and 
assessed protein. Tumor mass and secretory activity alter serum levels of CgA and it is 
thought that CgA correlates with tumor burden. Although, various non-malignant diseases 
also induce elevated serum levels of CgA, such as renal insufficiency, Parkinson’s disease, 
liver disease, pregnancy, and in patients taking proton pump inhibitors (PPI) CgA levels are 
also increased 43. Contrarily, CgA levels may decrease during a therapy with somatostatin 
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analogs 44. The sensitivity varies between 60 – 100 %, with a better sensitivity in metastatic 
disease than in patients with localized tumors 43, 45. In patients taking consistent doses of 
somatostatin analogs a rise of CgA levels is highly suspicious for tumor growth and/or loss of 
secretory control 46, 47. Taken together screening or testing with CgA for pNET is not 
recommended.  
A biomarker panel consisting of CgA and pancreatic polypeptide increases the sensitivity for 
diagnosis of nf-pNET to 94 % 48. 
In recent years the approach of functional localization of pNETs by assessment of hormone 
concentrations in the portal blood has disappeared almost completely from clinical routine. 
This technique was used to establish the diagnosis of an insulinoma, which was not seen 
with conventional imaging methods. The original portal-venous-sampling was replaced 
subsequently by selective-arterial injection of secretin (to detect gastrinomas) or calcium (to 
detect other pNETs) combined with angiography. Selective intra-arterial injection of calcium 
in combination with hepatic venous insulin sampling is proven to be a sensitive (88 – 100 %) 
diagnostic tool to localize insulinomas 49, 50.  
Since, imaging modalities has improved there is almost no indication left for these special 
kinds of examination. Nowadays it is occasionally applied in patients with insulinomas or 
gastrinomas not localized by other diagnostic methods 49, 51. 
 
 
1.5 Functional pancreatic neuroendocrine tumors 
1.5.1 Insulinoma 
This entity is the most common functional pancreatic neuroendocrine tumor, presenting with 
autonomous insulin production. An estimated incidence of 1 – 3 per million population per 
year is reported 17, 52. Insulinomas are usually benign (85 – 95 %), single tumors and become 
clinically apparent with Whipple’s Triad, although, there is a delay in diagnosis on average of 
four years 53. The classical clinical signs are symptoms of hypoglycemia, high insulin levels 
with plasma glucose levels  < 50 mg/dl and relief of symptoms after administration of glucose 
(Whipple’s Triad) 54. Furthermore, insulinomas cause neuroglycopenic symptoms, such as 
confusion, visual changes and coma, or as well symptoms due to hypoglycemia, such as 
weakness, sweating and tachycardia. Due to these various symptoms a significant number of 
patients is initially admitted to psychiatry. Typically patients develop symptoms after fasting 
or exercising. Drawing conclusions from the severity of the symptoms on the tumor burden is 
not possible 55, 56.  
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The gold standard for diagnosing an insulinoma is supervised fasting for 72 hours with 
documentation of glucose and insulin blood levels. About 30 % of patients have ailment 
within 12 hours, 80 % at 24 hours, 90 % at 48 hours and 100 % at 72 hours 53. To rule out 
insulin misuse the blood levels of C peptide and/or proinsulin should be measured. If these 
levels are increased the diagnosis of Insulinoma is established 57. Insulinomas may be a part 
of MEN-1, in which case the tumors are almost always multiple and difficult to diagnose. 
After the endogenous hyperinsulinism is proven the tumor mass has to be assessed. As 
mentioned above, there are plenty of imaging modalities to determine the dimension of the 
disease. Genetic testing should also be done to rule out MEN-1, as therapy strategy differs 
substantially between MEN-1 and a sporadic insulinoma. 
 
1.5.2 Gastrinoma 
Gastrinomas ectopically secrete gastrin, which leads to Zollinger-Ellison syndrome (ZES). 
ZES is characterized by peptic ulcer disease (stomach and duodenum), abdominal pain, 
secretory diarrhea and gastroesophageal reflux disease. Similar to insulinoma there is a 
delay in establishing the diagnosis of a gastrinoma of about six years. Gastrinomas are 
malignant in 60 – 90 % of cases, usually small (< 1 cm) and in 60 % gastrinomas are found 
in the duodenal wall in patients with sporadic ZES. This rate increases up to 85 % in patients 
with MEN-1/ZES, moreover, these patients always develop multiple tumors 17, 52, 58-60.  
If ZES is suspected fasting gastrin level has to be measured and PPIs need to be ceased 
seven days prior to the blood test. Additionally, a gastroscopy has to be done to take 
biopsies and measure gastric pH. The diagnosis is verified when serum gastrin is > 1000 
pg/ml, gastric pH is < 2 and biopsies lack to prove atrophic gastritis. If gastrin is moderately 
elevated (100 – 1000 pg/ml) a secretin test is required because gastrinomas ectopically 
express secretin receptors. Intravenous administration of secretin provokes increased 
secretin secretion by the gastrinoma. An accentuation of secretin blood level of > 120 pg/ml 
is argumentative for a gastrinoma with a sensitivity of 94 % and a specifity of 100 %, if the 
patient is not taking PPIs 58, 61, 62.  
Recent studies indicate that the widespread use of PPIs may mask the symptoms of ZES 
and therefore delay the diagnosis. This is because PPIs, in contrast to H2-receptor 
antagonists, attenuate the symptoms of acid hypersecretion in most ZES patients. Moreover, 
PPIs lead to elevated gastrin levels in non-ZES patients. PPI treatment may lead to 60 % of 
gastrin levels of ZES patients 61, 63.  
Another problem in detecting ZES in MEN-1 patients may be due to hypercalcemia after 
sufficient treatment of hyperparathyroidism. Hypercalcemia influence fasting gastrin levels, 
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basal acid output and the secretin test hence hinder the diagnosis 64.  
 
1.5.3 Glucagonoma 
The eponymous secreted hormone of this tumor is glucagon, which causes glucose 
intolerance (40 – 90 %), weight loss (80 %) and a pathognomonic rash, called migratory 
necrolytic erythema (70 – 90 %). This neoplasia is commonly malignant, large at diagnosis 
(mean 6 cm) and in more than 60 % liver metastases are apparent 65, 66.  
Clinically significant hyperglycemia occurs in only half of the patients. The migratory 
necrolytic erythema is caused by direct glucagon infusion and leads in some cases to the 
diagnosis – made by a dermatologist. Raised erythematous patches beginning in the 
perineum and progressing to the trunk and the extremities characterize this rash. However, 
the rash is not characteristic for glucagonoma, since it also occurs in celiac disease, cirrhosis 
and pancreatitis 67.  
To establish the diagnosis of a glucagonoma extraordinary elevated glucagon serum levels 
have to be demonstrated (500 – 1000 pg/ml) in a patient 65. 
 
1.5.4 VIPoma 
Verner and Morrisson first described the typical symptoms of this disease in 1958 (Verner-
Morrisson syndrome) 68, which are diagnostic. These symptoms include watery diarrhea,     
(> 700 ml/d in 100 %, > 3000 ml/d in 70 – 80 %), hypokalemia (70 – 100 %) and 
hypochlorhydria (35 – 76 %). The large volume diarrhea often leads to dehydration and 
electrolyte disturbances, a metabolic acidosis is also seen due to the fecal loss of 
bicarbonate. At presentation the tumors are metastatic in 70 – 80 % of patients, however 
VIPomas are usually single tumors. To secure diagnosis measurement of elevated serum 
VIP level (> 500 pg/ml) in combination with high volume diarrhea is required 69-71.  
 
1.5.5 Somatostatinoma 
Somatostatinomas are the least common of the five well-described f-pNETs. These tumors 
are usually single tumors, either found in the duodenum (50 %) or in the pancreas (50 %) 
and half is malignant. The classical symptoms accompany a somatostatinoma are diabetes 
mellitus, gallbladder disease, weight loss, diarrhea, steatorrhea and anemia. Because of the 
unspecific symptoms the diagnosis of a somatostatinoma is even later confirmed. There is no 
reliable provocative test to detect a somatostatinoma. To confirm the diagnosis a pancreatic 
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tumor combined with typical symptoms and elevated serum levels of somatostatin are 
recommended 65, 72, 73.   
 
 
 Fig. 1. Clinical presentation of the different pNETs 74  
 
 
1.6 Classification 
1.6.1 Evolution of classification systems 
Since Oberndorfer 2 first mentioned carcinoids over 100 years ago there were different 
attempts to categorize these tumors. In 1980, the WHO used the term carcinoid for every 
tumor of the neuroendocrine system, “excluding pancreatic endocrine tumour [sic!] (islet cell 
tumour [sic!]), medullary carcinoma of the thyroid, paraganglioma, small cell lung carcinoma 
and Merkel cell tumour [sic!] of the skin” 75. This classification subdivided the tumors on the 
basis of different staining methods but failed to estimate patient outcome. Besides the 
ambiguous term carcinoid the medical society used inaccurate descriptions such as local, 
locally advanced and metastatic. 
Capella et al. published a landmark study in which they introduced the term “neuroendocrine 
tumor” instead of carcinoid, which implies the whole neuroendocrine tumor entity. Moreover, 
this working group proposed further statements to finally establish guidelines for the clinician. 
Their classification subdivided the tumors into tumors with benign behavior, uncertain 
behavior and into low malignancies, resulting in highly malignant neoplasms (Figure 2) 75.  
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Fig. 2. Scheme of the different neuroendocrine tumors postulated in 1995 by Capella et al. 75 
 
Based on this work the WHO published in 2000 a classification for gastroenteropancreatic 
neuroendocrine tumors. This classification adopted the idea to subdivide the tumors by their 
dignity and therefore distinguish between well-differentiated tumors (with benign and 
uncertain behavior), well-differentiated neuroendocrine carcinomas and poorly differentiated 
carcinomas 76. The prognostic value of this classification system has been proved in several 
studies 15, 77, 78.  
Nonetheless, this classification system failed to be adopted into clinical routine, thus in 2006 
a consensus proposal including a grading system was published. From this proposal evolved 
the ENETS their guidelines for neuroendocrine tumors, including pNETs, published in the 
same year and adapted in 2012. The ENETS guidelines refer to the tumor-node-metastasis 
(TNM) system in combination with a grading classification based on the mitotic rate and/or 
Ki-67 proliferation index 4 5, 6.  
In 2009 the AJCC presented the 7th edition of the AJCC manual and for the first time the 
manual contained a staging classification for neuroendocrine tumors 8. Unfortunately, the 
TNM staging for pNET is derived from exocrine pancreatic adenocarcinoma.  
In 2002 another classification system was published, which is called Hochwald classification 
system 79. This classification system focuses on well-differentiated pNETs and a recent study 
even showed its superiority to ENETS and AJCC guidelines in this subdomain when it is 
combined with proliferation Ki-67 index 79. 
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Moreover, the North American Neuroendocrine Tumor Society (NANETS) also developed 
guidelines. These guidelines were published in 2010 and concern both clinical management 
and histopathological diagnostics of pNETs 80, 81.  
The ENETS and the AJCC staging system are worldwide in use, however, differ in several 
significant points, which will be highlighted in the next sections. Due to the discrepancies of 
the two main staging systems awareness has risen that this will lead to disarrangement in 
clinical routine and hinder scientific communication 82.  
 
1.6.2 ENETS guidelines 
The ENETS guidelines are based on the published experience of single centers and were 
devised at the first ENETS Consensus Conference in November 2005. Since then the 
guidelines were confirmed at least in seven autonomous surveys 83-89 and were revised at the 
second ENETS Consensus Conference in 2012 and published subsequently 5, 6. 
The classification system is based on a 4-stage TNM classification combined with a grading 
classification (low, intermediate, high). From ENETS standpoint in 2005 there was no grading 
system that accurately predicted the behavior of well-differentiated endocrine tumors. Hence, 
the society decided to incorporate a grading classification into their guidelines. The grading 
classification was established referring to the contemporary WHO criteria. The three tumor 
categories are discriminated due to their proliferation status determined by mitotic count 
and/or Ki-67 index (Figure 3) 4.  
 
 
Fig. 3. The grading system for pNETs, published by ENETS 4 
 
Although the grading of the tumor is important there are groups who want to adapt the 
grading scores. In a study the proliferation index was evaluated and the authors suggest 
determining new cut-off levels for Ki-67. They reached prognostic stratification within the 
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groups not before they set the cut-off at 5 – 20 % 87. 
The ENETS guidelines, as other TNM classifications, postulate four stage classes (I – IV), 
whereat stage II and III are subdivided into IIA, IIB and IIIA and IIIB, respectively. Recently, it 
was demonstrated that death risk ascend statistically significant from stage I to stage IV 89.  
Another working group published a retrospective study purporting survival rates at 5 years 
after foregut NET (stomach, duodenum, pancreas). The survival rates for stage I was 100 %, 
for stage II 89,5 %, for stage III 79,1 % and for stage IV 55,4 %. However, there was only 
statistical significance between stage I vs. IV, whereas the difference between stage I vs. II 
and stage II vs. III was not significant. As mentioned above, this study included NETs of the 
stomach, the duodenum and the pancreas 86. 
 
1.6.3 AJCC guidelines 
In 2007 Bilimoria et al. published a study to prove the prognostic value of the AJCC TNM 
manual (6th edition) for pancreatic adenocarcinoma for pNETs. The authors identified 
patients from the National Cancer Data Base (1985 – 2004) to test their hypothesis. After 
evaluation of their data, they postulated “the staging system can effectively stratify patients 
with pNETs” and “provides survival discrimination by stage for surgical and nonsurgical 
patients” 90. It was not until 2010 that the AJCC guidelines for pNETs were published 8 and 
may be built on these findings. Unfortunately the guidelines for pNETs were derived from 
those for exocrine adenocarcinoma. In contrast to the ENETS guidelines the AJCC 
classification is based on a cancer registry database publication and up to now was validated 
only once. This study concluded that “the AJCC TNM classification is prognostic for overall 
survival and can be adopted in clinical practice”. Nonetheless the survival comparison 
between stages I vs. II and II vs. III were not statistically significant, although the difference 
between stages I vs. IV was significant 10. The AJCC TNM manual distinguishes between 
localized (stage I), locally advanced resectable (stage II), locally advanced unresectable 
(stage III) and distantly metastasized tumors (stage IV).  
 
The two main guidelines differ in the definitions of T stages, obviously mainly in T2 and T3 
and it is reported that this difference can affect the prognostic value. The 10 year prognosis 
in patients with ENETS stage I tumors is 96 % in contrast to patients suffering from AJCC 
stage I tumors (71 %). It is supposed that this is caused by the inclusion of ENETS stage II 
tumors in AJCC stage I 87, 91.  
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Another main distinction is the AJCC recommendation to record the tumor grade but the 
manual lacks a specific guideline for grade assignment.  
 
Fig. 4. UICC (left) and ENETS (right) classification system 80 
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1.7 Treatment 
1.7.1 Surgery 
Although, management of patients with pNET is achieved via a multidisciplinary evaluation 
and treatment, surgery is the only potentially curative strategy for these patients 11. A 
retrospective study including 728 patients with pNET compared the survival times of patients 
who underwent surgery and those who did not. Patients whose tumor was resected had a 
mean survival of 60 months compared to 31 months in the non-operative group, which is 
statistically highly significant 92.  
Furthermore, surgery can control hormone secretion and accompanied syndromes. Since it 
is known that PPI treatment is highly effective in ZES patients, however, gastric surgery is no 
longer indicated to reduce acid secretion in ZES patients.  
When surgery is considered preoperative staging has to be completed and the tumor 
detected. Nonetheless, if the diagnostic tools fail to do so, explorative laparotomy can be 
performed to localize and resect the tumor. The literature demonstrates that an experienced 
surgeon mostly (> 95 % of insulinomas or gastrinomas) localize the pNET 59, 93. Therefore 
blind pancreatectomy in the case of no detected tumor is not indicated. When surgical 
resection of a pNET is done it is recommended to perform an accurate exploration of the 
whole abdomen, followed by an intraoperative ultrasonography of the pancreas and in some 
cases duodenotomy is indicated. Intraoperative ultrasonography is also useful to identify the 
main pancreatic duct and therefore plan the resection. Duodenotomy is recommended for 
tumors with a predilection site for the duodenum such as gastrinomas or somatostatinomas 
94. 
If the tumor is small (< 2 cm) and expectably benign (i.e. insulinoma), a parenchyma sparing 
operation is indicated. As more than 90 % of insulinomas are benign enucleation has 
become the standard procedure. If the tumor is too big for enucleation a spleen-preserving 
distal pancreatectomy is generally preferred (Kimura’s procedure) 95.  
A laparoscopic approach for small benign tumors is well established, since the first 
successful series in 1996 96. Since then laparoscopic surgery is reserved for tumors located 
in the body or the tail, resected either by enucleation or by spleen-preserving distal 
pancreatectomy. It has been shown that laparoscopic pancreas surgery is a safe procedure 
and pancreatic fistulas are not more frequent than in open surgery 97. Nonetheless, if there 
are signs of malignancy, such as local invasion or distant metastases, or 
pancreaticoduodenectomy is indicated conversion to open surgery is obligate.  
A more radical operation is indicated if the tumor is potentially malignant or bigger than 2 cm 
or located in the head of the pancreas. The extent of lymphadenectomy required is still 
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controversial due to the fact that there is no correlation identified between lymph node 
metastases and overall survival 15, 98. nf-pNETs often get clinical apparent due to mass 
effects and patients often suffer from distant metastases at diagnosis. Patients with such 
advanced disease should also be considered for surgery, although this is possible only in 
selected patients. Debulking surgery in these patients should target to resect at least > 90 % 
of the tumor burden, although hepatic recurrence is high, with up to 76 % of patients with 
recurrent metastases to the liver within two years 80, 99.  
The surgical management in patients with hereditary syndromes differs to patients with 
sporadic pNETs. The timing and extent of surgery for nf-pNETs in patients with MEN-1 is still 
controversial. In patients with MEN-1 nf-pNETs are multifocal and local resection is not 
expected to result in cure. Nonetheless, there is consensus that nf-pNETs in MEN-1 patients 
bigger than 2 cm or tumors that cause symptoms should be resected. Smaller tumors are 
treated differentially in diverse centers. There are groups who propose surgery if the tumor 
size is 1 cm 100, 101. ENETS recommends surgery for nf-pNETs at 2 cm 102. If surgery has to 
be done for small, potentially benign nf-pNETs in MEN-1 patients, parenchyma sparing 
procedures are recommended because subsequent surgery is often necessary.  
Inuslinomas in patients with MEN-1 are usually resected as described above 30. The surgical 
management of MEN-1 ZES was controversial discussed recently 94. Due to the fact that liver 
metastases will occur in 23 – 39 % in patients with MEN-1 ZES an aggressive approach is 
recommended. After pylorus-preserving pancreaticoduodenectomy (PPPD) the risk of distant 
liver metastases is declined to 3 – 5 % 103. 
 
1.7.2 Symptomatic management 
Insulinomas are treated surgically with excellent cure rates, however, symptom control has to 
be achieved prior to surgery and in patients with malignant disease. A first step to relieve 
symptoms is dietary modification with frequent small feedings. To control insulinoma induced 
hypoglycemia more reliable administration of diazoxide (200 – 600 mg/d) is used. Diazoxide 
is a benzothiazide and therapeutic success is achieved in 50 – 60 % of patients. Side effects, 
such as fluid retention (frequent), nausea and occasional hirsutism (at higher doses), may 
occur and require additional medication like diuretics 42, 53, 104. Long-acting somatostatin 
analogs (octreotide, lanreotide) can also ease hypoglycemic symptoms in up to 50 %. 
However, they have to be used with caution, as they may worsen the hypoglycemia 38. 
Gastrinomas ectopically secrete gastrin, which leads to ZES. By now PPIs are the gold 
standard agents to control the acid hypersecretion in almost every patient with ZES. H2-
receptor antagonists and somatostatin analogs are also effective but frequently high doses 
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have to be administered. PPIs are taken once or twice a day in standard doses (i.e. 40 mg 
omeprazole). Higher doses are needed in patients with MEN-1 or severe gastroesophageal 
reflux or prior Billroth II resection. Data on long-term usage of PPIs in ZES patients 
demonstrates no evidence of tachyphylaxis and an excellent safety profile 58, 105, 106.  
Other f-pNETs are treated with long-acting somatostatin analogs (octreotide, lanreotide), 
which is effective in the initial management of glucagonomas, VIPomas and in some 
somatostatinomas. Due to recent formulation of the drugs a monthly depot injection is 
sufficient which is a great advancement and leads to higher patient convenience. Octreotide 
can reduce serum VIP levels in patients with VIPoma in > 80 % and ease diarrhea in > 75 %, 
however this excellent response rates are short-lived without increase in the dosage. 
Adverse effects of somatostatin analogs are generally mild, including flatulence 
diarrhea/steatorrhea, nausea, gallstones, and glucose intolerance 102, 107, 108.  
 
1.7.3 Liver directed therapy 
As mentioned above, synchronous liver metastases should be treated surgically if > 90 % of 
the tumor burden can be removed 80, 99. Repeated resection for resectable recurrent disease 
is favored and overall 5-year survival rates of 65 % can be achieved 100, 109.  
If complete surgical resection of all liver metastases is not feasible, a combination of 
resection and ablation can be employed. Radio frequency ablation (RFA) can be used alone 
or in conjunction with cytoreductive surgery; if RFA is applied alone this is possible via a 
percutaneous or laparoscopic approach. Advantages of RFA are a low morbidity (< 15 %), 
high response rates (90 – 95 %), symptom relief is often achieved (> 95 %) and RFA can be 
repeated if necessary. Limiting factors for RFA are tumor location, size and number 110-112.  
Patients with unresectable liver metastases can be treated with embolization methods to 
control hormone symptoms or as a palliative therapy. Liver metastases derive their blood 
supply basically from hepatic artery branches, hence they are targeted via transarterial 
embolization. The techniques of embolization range from bland embolization to embolization 
with chemotherapeutic agents or embolization with radionuclides.  Transarterial 
chemoembolization (TACE) uses beads coupled with conventional chemotherapeutic agents 
(such as doxorubicin, cisplatin, streptozocin) and is typically repeated every 6 – 8 weeks. 
There are various studies, which report on a symptom relief in 50 – 100 % and a tumor 
shrinkage in 25 – 86 % 45, 113.  
More recently, beads coupled to radionuclides are used to deliver ionizing radiation directly 
into the tumors. For internal radiotherapy administration of Yttrium-90 (Y-90) particles are 
used with promising results. A prospective study with 34 patients showed radiologic 
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response in 50 % including 18 % with complete response 114.  
The side effects of embolization therapy are low, including pain, nausea and fever. 
Contraindications to TACE and other embolization procedures include liver dysfunction, 
portal venous thrombosis and history of biliary reconstruction 115. 
 
1.7.4 Chemotherapy 
1.7.4.1 Somatostatin receptor pathway 
Somatostatin, physiologically produced in the brain, pancreas, stomach and intestine binds 
to G-protein-coupled somatostatin receptors and influences on cell growth and 
neurotransmission processes. There are 5 known somatostatin receptors subtypes: sst1, 
sst2, sst3, sst4 and sst5. Approximately > 80 % of pNETs express somatostatin receptors. 
Traditionally, somatostatin analogs are used in patients with large tumors and in patients 
suffering from hormone hypersecretion. A prospective study (PROMID) investigated the 
value of long-acting octreotide in patients with low-grade metastatic NET of the midgut. The 
study could demonstrate that treatment with octreotide could double the time to progression 
compared with placebo (14,3 months vs. 6 months) 116, 117. A subsequent multi-center study, 
which used lanreotide (CLARINET), could prove these results. Their study population 
consisted of patients with metastatic disease with a Ki-67 index < 10 % and the progression-
free survival could significantly be prolonged 118. Nonetheless, no study could demonstrate 
so far how the anti-proliferative effects of the biotherapy were functioning.  
1.7.4.2 Traditional chemotherapy 
Different agents have been tested in patients with advanced pNETs and some efforts were 
made. The first agent with proven significant benefit was streptozocin, however, due to 
severe side effects this approach has been left 119. Over time many different combinations of 
vrious agents were tried out, with most effects seen with streptozocin/doxorubicin, 
streptozocin/fluorouracil or streptozocin/doxorubicin/fluorouracil 120, 121. The three-drug 
regimen was associated with an overall response rate of 39 % and median survival duration 
of 37 months 122.  
1.7.4.3 mTOR pathway 
The mammalian target of rapamycin (mTOR) is an intracellular serine-threonine kinases that 
influences cell growth, proliferation, metabolism and apoptosis and is upregulated in many 
cancer types. Temsirolimus and everolimus are rapamycin derivatives, which have been 
evaluated in clinical trials for the treatment of patients with pNETs. Temsirolimus reached an 
objective response rate of only 5,6 % in a phase II study of 37 patients. Hence further 
monotherapy studies with temsirolimus were not pursued 123. 
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Everolimus was initially evaluated in a study of 60 patients with neuroendocrine tumors of 
which 30 patients suffered from a pNET. In this study everolimus was combined with a long-
acting release form of octreotide. The 30 patients with pNET showed an overall tumor 
response rate of 27 % and a progression-free survival (PFS) of 50 weeks 124.  
Based on these findings a phase II clinical trial (RADIANT-1) was initiated. RADIANT-1 
included 160 patients with metastatic pNETs receiving either everolimus as a single agent or 
everolimus combined with octreotide LAR. Median PFS was longer in the combination group 
(16,7 vs. 9,7 months) 125. Subsequently, RADIANT-2 and RADIANT-3 were drafted and 
proved that everolimus, with or without octreotide LAR, prolong the median PFS compared to 
placebo, with or without octreotide LAR. The median PFS reached in RADIANT-2 was 16,4 
vs. 11,3 months and in RADIANT-3 11 vs. 4,6 months. The side effects of everolimus 
treatment are mild, including stomatitis, rash, diarrhea and fatigue. 126, 127 Multiple trials 
investigating the use of everolimus in combination with other agents in patients with pNET 
are ongoing (www.clinicaltrials.gov). 
1.7.4.4 VEGF pathway 
Angiogenesis in tumor growth is a well-established phenomenon. Vascular endothelial 
growth factor (VEGF) plays an important role in angiogenesis and the VEGF-family consists 
of 6 proteins interacting with 3 receptors (VEGFR-1, VEGFR-2, VEGFR-3). VEGFR-2 is 
thought to be the most important factor in tumor cell angiogenesis 128. For clinical purpose 
there are agents available interfering directly with VEGF (bevacizumab) or block the receptor 
(sunitinib, sorafenib).   
Bevacizumab is a monoclonal antibody that binds to circulating VEGF and has to be 
combined with a cytotoxic agent for most solid tumors. Combination therapy with 
bevacizumab in patients with pNETs has been undertaken. In one study Bevacizumab was 
combined with temozolomide including 18 patients with pNET. Four patients with pNET 
showed partial response 129. In a more recent study 55 patients with pNETs were treated with 
a combination of temsirolimus and bevacizumab. The response rate in this study was 37 %. 
49 patients were evaluated for PFS and in this population 49 % were progression-free at 12 
months 130.  
Sunitinib inhibits all 3 VEGFRs and some other tyrosine kinase receptors. In a first study 
efficacy of sunitinib was proven in patients with pNET showing a response rate of 16,7 % 131. 
Based on these findings a phase III clinical trial was enrolled which should include 340 
patients with well-differentiated pNETs. After analyzing the first 171 patients the ongoing 
study was discontinued due to an increased number of deaths in the placebo group. Patients 
in the verum group had a PFS of 11,4 months compared to 5,5 months in the placebo group. 
Reported side effects of sunitinib were neutropenia, hypertension and fatigue 132. 
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Sorafenib blocks VEGFR-2 and some other tyrosine kinase receptors, however, this agent 
has only moderate effects on pNETs. In a study with 43 patients suffering from metastatic 
pNET only 10 % had partial response and 6-month PFS was seen in 14 of 23 evaluable 
patients 133.  
 
1.7.5 Liver transplantation 
Liver transplantation was performed in patients with metastatic pNETs. The reported series 
of patients treated with liver transplantation for metastatic pNET are very small. According to 
the literature the optimal patient for liver transplantation is young (< 50 years), the tumor is 
not resectable and limited to the liver and shows a favorable histology with a low Ki-67 index 
and causes hormonal symptoms. Nonetheless the results for liver transplantation in patients 
with metastatic pNET are disappointing. In a recent review with 85 cases the overall 5-year 
survival was 45 % 134, 135. 
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2 Aim of the study 
Pancreatic neuroendocrine tumors represent only 1 – 2 % of all pancreatic neoplasia.  
Firstly, aim of this study was to identify patients who underwent a pancreatic resection 
because of a pNET between 1996 and 2011 at our institute.  
Secondly, a detailed characterization of the patients was necessary to interpret prognostic 
factors.  
Thirdly, the focus was on the prognostic value of pathologic diagnostic criteria as in ENETS 
and TNM staging guidelines.  
Thirdly, the postoperative course and complication rate in the study population was analyzed 
and the impact of various factors on the morbidity should be analyzed.  
Fourthly, the survival rates and their influencing factors should be evaluated. 
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3 Material and methods 
3.1 Assessment 
Between June 1996 and November 2011, 66 consecutive patients with a pancreatic 
neuroendocrine tumor were operated at our institute. All patients with histologically confirmed 
pNETs were included in this study. The tumor burden of these 66 patients was resected. 
Patients who just have undergone explorative laparotomy were excluded. Patient data were 
entered into a computerized database, and follow up was recorded for each patient available. 
Median follow up for all patients was 39,2 months. All data were analyzed with respect to 
demographic data (patient age, gender), hospital stay, characteristics of the primary tumor, 
type of surgical resection and quality of resection. The length of the postoperative hospital 
stay period was defined as the interval from the day of surgery to discharge. The calculation 
for overall survival started at the date of surgery. 
Pathological parameters analyzed were tumor diameter (T), regional lymph node status (N), 
resection margin status (R) and tumor grade (G). Furthermore, reports on distant metastasis 
(M) were also included. Grading was determined according to the ENETS guidelines 4. Ki-67 
immunohistochemistry was available in 31 tumor sections. When Ki-67 
immunohistochemistry was not available, the histological report contained the mitotic count 
and/or clearly stated the tumor grading.  
Postoperative pancreatic fistulas were defined according to the International Study Group of 
Pancreatic Surgery (ISGPS) 136.  
For statistical analyses patients were divided into living and deceased patients. One patient 
(1,52 %) was lost for follow up and was excluded from statistical analyses regarding 
outcome. Patients who died within 30 days after operation were also excluded from these 
analyses. 
Since the analysis period is long not all medical reports are complete. If this was the case 
and a detail was missing this patient was not considered for the special analysis.  
With the clinical and histological information patients were subdivided into the two main 
classification systems – the ENETS and the UICC classification system.  
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3.2 Surgical procedures 
Surgical strategy was based on anatomic and oncologic demands. According to the above 
mentioned findings the resection was planned and executed. For potentially malignant 
tumors in the head the classic pancreatic head resection or pylorus-preserving 
pancreaticoduodenectomy was chosen. For small and potentially benign tumors an organ-
preserving approach was preferred. For left-sided lesions a distal pancreatectomy was 
chosen and if possible this was done spleen-preserving. Distal pancreatectomy was also 
done laparoscopically. Segmental pancreatic body resection was performed for central 
tumors and if necessary a total pancreatectomy was done in selected patients. Lymph nodes 
were dissected when extensive surgery was carried out. Debulking procedures where the 
primary tumor was resected were performed in combination with liver resection, 
hemicolectomy, splenectomy or gastric resection.  
 
 
3.3 Statistical analysis 
Overall survival, complication rates and other parameters (operation time, hospital stay) were 
assessed. An excel file was designed and these data were transferred into IBM SPSS 
Statistics 20. First a descriptive analysis was done. 
For statistical analysis SPSS 20 was used. The survival rates were assessed with Kaplan-
Meier methods and compared with the log rank test. Hazard ratios and corresponding 
confidence intervals (CI) were calculated. Only risk factors with a p-value of < 0,2 in 
univariate analysis were considered for multivariate analysis. The influence of variables was 
evaluated with the Cox regression model 137.  
The morbidity was analyzed with Chi-square test in an univariate setting with crosstabs first. 
Thereafter, multiple logistic regression was used in the multivariate analysis. Again only 
variable with a p-value < 0,2 were considered for further analysis. Furthermore, regression 
coefficient and Hazard ratio with 95% confidence interval were collected 138. 
A p-value < 0,05 was considered significant. If possible data were presented as mean values 
± standard deviation. 
The databank was established with Excel for mac 2011. Word for mac 2011 was used to 
write the thesis and references were managed with EndNote 6.0.2. Data are displayed either 
with SPSS 20 or with GraphPad prism version 4.0. 
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4 Results 
4.1 Characterization of the analyzed group 
The analysis included 66 patients, 33 female and 33 male. The analyzed cohort was of 
median age of 59,1 years (31 – 83). Figure 5 shows the distribution to different age groups 
with most patients operated between 60 – 69 years (31.8 %). The median age of patients 
was 62,5 years (31 – 83 years) at the time of the operation.  
 
 
Fig. 5 Age pattern at the time of operation  
 
The tumor of every patient investigated in this study was resected, hence the population 
does not include patients who only had undergone explorative laparotomy. Patients with 
pNET who are considered only for palliative care are also not included.  
Various resection regimens were adopted to the patients. The tumor mass of 22 patients was 
resected via a pancreas head resection. Distal pancreatectomy was performed in 30 cases 
while complete pancreatectomy has do be done in five patients. Less invasive approaches 
were applied to eleven patients (five enucleations and four segmental resections). Resection 
of the tumor mass was accompanied in 35 % (n = 23) with an additional procedure like 
cholecystectomy or splenectomy.  
Unfortunately the medical history of one patient is not complete, especially the 
histopathology report is inconclusive.  
Furthermore, the postoperative outcome of one patient is not clear, as the patient could not 
be reached and the archive has only parts of the file. Therefore, the mentioned patient is not 
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included in calculations regarding the outcome. 
The 30-day mortality in the analyzed group was 4,5 % (n=3), subsequently, these three 
patients were also excluded from any calculations concerning overall survival. Two of these 
three patients had a pancreatic head resection and one a distal pancreatectomy. 
Interestingly, all three patients had a history of pancreatitis, either prior to the operation or 
thereafter. The cause of death of one patient (head resection) was not directly related to the 
operation as this patient died because of heart failure. The two other patients suffered 
complications directly related to previous surgery and as a consequence re-operations were 
necessary. Nonetheless, both died of multi organ failure within 30 days.  
 
female	 n	=	33	
male	 n	=	33	
age	(years)		 59,1	(31	-	83)	
pancreatic	head	resection	 n	=	22	
pancreatectomy	 n	=	5	
distal	pancreatectomy	 n	=	30	
segmental	resection	 n	=	9	
 
Fig. 6 Characterization of the analyzed cohort 
 
 
4.2 Surgery 
As mentioned above different resection strategies were used for the diverse patients and 
tumor localizations. Five patients were treated with enucleation and four with segmental 
resection and as a consequence lymph node sampling was done only in 54 patients (84 %).  
Five of the 30 (17 %) distal pancreatectomies were done via a laparoscopic approach. 
Lymph nodes were resected in four of these five cases (80 %). The laparoscopic approach 
required a mean operation time of 185 minutes (± 18,84 minutes) compared to 214,4 minutes 
(± 12,31 minutes) with the open procedure. This difference is statistically not significant.  
Regarding the duration of the operation there is a statistically significant difference between 
deceased and living patients. Mean operation time of living patients was 183,1 minutes (± 
12,74 minutes) and operation time of deceased patients averaged 253,7 minutes (± 19,19 
minutes) (Figure 7 a). However, there was no significant difference in relation to the hospital 
stay between living and deceased patients (17,84 ± 2,18 days vs. 17,46 ± 1,41 days) (Figure 
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7 b). Furthermore, there is no significant difference evaluating the age of these two groups. 
Living patients were 58,18 years (± 2,29 years) at the time of operation, whereas the 
deceased population had a mean age of 60,37 years (± 2,57 years) (Figure 7 c).  
 
 
 
Fig. 7 a, b, c Differences between the operation time (a) (* p < 0,05), the hospital stay (b) and the age 
(c) of living and deceased patients.  
 
In a subgroup analysis the different kinds of operations were analyzed. The operation time of 
the two main groups – pancreatic head resection and distal pancreatectomy – was 
evaluated. Neither was there a statistical significant difference of the operation time of the 
living and the deceased people in the pancreatic head resection group, nor was there a 
significant difference in the distal pancreatectomy group (Figure 8 a). The age at operation 
and the duration of the hospital stay were also compared in the above-mentioned collectives. 
Again there was no significant difference when the living and the deceased patients were 
compared to each other (Figure 8 b, c). 
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Fig. 8 a, b, c Differences between the operation time (a), the hospital stay (b) and the age (c) of living 
and deceased patients for the different operation regimes.   
 
The cohort investigated in this study suffered from different complications. Pancreatic fistula 
was seen in 13 patients (19,7 %) and five patients required an interventional drainage 
(ISGPS B).  
25 patients of the analyzed cohort received any kind of anastomosis and anastomotic 
leakage developed in nine of these patients (36 %). Only one patient developed a leakage of 
the gastrojejunostomy and subsequent operation was necessary in this patient because of 
the insufficiency. An insufficiency of the pancreaticojejunostomy was detected in 3 patients. 
The most common kind of anastomotic leakage was an insufficiency of the 
hepaticojejunostomy, which was observed in five patients. Moreover, four of these patients 
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necessitated reoperation due to the insufficiency.  
Six patients (9,1 %) of the investigated cohort had to be re-operated because of a 
complication. Four patients suffered from an insufficiency of the hepaticojejunostomy, one 
patient had an insufficiency of the gastrojejunostomy and one patient developed a 
pancreatitis after the initial tumor operation. 
 
 
4.3 Overall survival 
As mentioned above the postoperative outcome of one patient (1,5 %) is unknown and three 
patients are excluded from any survival calculation as they died within 30 days. As a 
consequence the calculation of the overall survival rate contains 62 patients. The median 
follow up period was 51 months (6 – 220 months) and the calculated mean overall survival 
was 130,17 months (CI95%: 103,21 – 157,14 months). The survival rate after one year was 
95 %, after two years still 87 % and after three years 80 %. The calculated 5-year survival for 
the analyzed cohort was 66 %. Figure 9 
 
 
Fig. 9 Calculated overall survival  
Results 
Florian Bösch  Seite 27 
 
4.3.1 Overall survival in regard to gender 
The survival rates of female and male patients were compared next. The distribution to the 
two groups was exactly equal, 31 female and 31 male patients. The survival rates did not 
differ significantly between the two groups. The calculated mean overall survival for female 
patients was 151,37 months (CI95%: 117,03 – 185,72) compared to 79,3 months (CI95%: 
63,53 – 95,08) for male patients (p=n.s.). Figure 10 
 
 
Fig. 10 Survival rate regarding the gender of the patients (p=n.s.). Blue line: female, green line: male  
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4.3.2 Overall survival in regard to age 
The impact of the age of patients at the time of operation was also highlighted. Our analysis 
revealed no influence of the age since overall survival rates were not significantly different if 
patients were younger or older than the median. The calculated mean overall survival for 
patients who came below the median was 146,06 months (CI95%: 110,1 – 182,02). Patients 
exceeding the median age reached a calculated mean overall survival of 75,13 months 
(CI95%: 58,21 – 92,05) (p=n.s.). Figure 11 
 
 
Fig. 11 Survival rate regarding the age of the patients (p=n.s.). Blue line: younger than median, green 
line: older than the median age 
 
 
4.4 TNM assessment and survival 
Clinical report on tumor size, lymph nodes, metastasis and resection status is missing for 
only one patient (1,5 %), however, a report on the tumor grading is available for this patient. 
Four patients were excluded from the calculation of the survival rates as three died within 30 
days in hospital and one patient is lost for follow up.  
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4.4.1 Tumor size (T) 
As mentioned above the tumor size of one patient is missing. 19 patients of the 65 patients 
were categorized to have a T1 tumor (29,2 %) and the patient lost for follow up had a T1 
tumor. T2 tumors were found in 14 patients (21,5 %), T3 tumors represent the biggest group 
with 25 patients (38,5 %) and T4 pNETs were found in 7 patients (10,8 %).  
Within these four groups the 3-year survival was best for patients with small tumors. This 
population showed a 3-year survival of 78 %, compared to a 3-year survival rate of 66 % in 
the T4 group. The 3-year survival rates for the T2 group and the T3 group are comparable to 
T1-tumors with 77 % and 75 %, respectively. The calculated mean overall survival of patients 
with a T1 tumor was 80,43 months (CI95%: 62,67 – 98,19 months) and patients with a T2 
tumor had an even better mean overall survival of 90,93 months (CI95%: 67,53 – 114,32 
months). The best calculated mean overall survival showed patients with a T3 tumor 118,89 
months (CI95%: 79,89 – 157,9 months). Lastly, T4 tumors had the worst outcome with a 
mean overall survival of 72 months (CI95%: 38,5 – 105,5 months). Figure 12.  
 
 
Fig. 12 Calculated survival rates illustrating the tumor size (T).  
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4.4.2 Lymph node (N) status 
Due to divergent operation methods and the partly missing medical history of one patient 
TNM assessment is not possible in every case. Besides the tumor mass lymph nodes were 
resected in 81,8 % (n=54), hence TNM staging is possible in these cases. The majority of 
these 54 patients did not show any positive lymph node (n=36; 66,7 %), however 18 patients 
(33,3 %) had at least one positive lymph node. No lymph node sampling was done in 11 
patients and the medical history of one patient is inconclusive regarding the lymph node 
status (18,2 %).  
The 3-year survival rates do not differ largely. Patients with no lymph node metastasis (N0) 
showed a 3-year survival rate of 77 % and patients with at least one positive lymph node 
(N1) reached 75 % survival after three years. This difference was statistically not significant 
(p=n.s.). Not surprisingly was the 3-year survival rate of patients with no lymph nodes 
resected best with 100 %.  
The calculated mean overall survival was concordant to the 3-year survival rates. Patients 
with no lymph node metastasis had a mean overall survival of 75, 58 months (CI95%: 59,96 
– 91,19 months) and patients with positive lymph nodes even 121,92 months  (CI95%: 71,96 
–171,88 months). The best calculated mean overall survival had patients with no lymph node 
resected 139,75 months  (CI95%: 112,17 – 167,33 months). Figure 13. 
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Fig. 13 Calculated survival rates illustrating the lymph node status (N) (N0 vs. N1, p=n.s).  
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4.4.3 Metastasis (M) status 
The medical reports about distant metastasis are complete for all 66 patients. When the 
operation was carried out 52 patients did not have distant metastases (M0; 78,8 %), 
however, 14 patients (21,2 %) had already a metastatic disease (M1).  
In an univariate analysis the two groups, either M0 or M1, showed statistical significant 
difference in survival rates. The 3-year survival rate for M0-patients was 85 % and for M1-
patients 60 % (p<0,05). These findings were confirmed by the calculated mean overall 
survival which was 150,23 months (CI95%: 120,08 – 180,39 months) for M0-patients and 
patients with a metastatic disease reached 48,83 months (CI95%: 29,9 – 67,76 months). 
Figure 14. 
 
 
Fig. 14 Calculated survival rates illustrating the metastatic status (M) (p<0,05). 
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4.4.4 Resection (R) status 
The results concerning the resection status are complete for all patients. The tumor mass of 
the big majority of patients (n=55; 83,3 %) was resected in sano (R0). However, the resection 
margins were not tumor free (R1) in eleven patients (16,7 %).  
The univariate analysis of the resection margins highlighted a statistical significant difference 
of the 3-year survival rates for R0 and R1. The population with a tumor free resection margin 
had a 3-year survival rate of 86 %, compared to 55 % in the R1 group (p<0,05). Patients with 
a tumor free resection margin showed a calculated mean overall survival of 152,07 months 
(CI95%: 123,74 – 180,4 months), however, patients with tumor infiltrated resection margins 
had only a mean overall survival of 51,65 months (CI95%: 28,09 – 75,2 months). Figure 15.  
 
 
Fig. 15 Calculated survival rates illustrating the resection margin (R) (p<0,05).  
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4.4.5 Grading (G) status 
The grading is conclusive for each patient. The biggest group represented G1 tumors with 45 
patients (68,2 %). The other third of the analyzed cohort were distributed to G2 and G3 as 
follows. 15 patients (22,7 %) were classified with a G2 tumor and 6 patients (9,1 %) were 
resected suffering from a G3 carcinoma. Taken together, G1 and G2 tumors represent the 
majority of resected tumors (91,4 %). 
The 3-year survival rate of the patients with a G1 tumor was 87 % and the G2 group showed 
a 3-year survival rate of 80 %. The group with G3 tumors was inferior to the other two with a 
3-year survival rate of only 33 %. As expected the calculated mean overall survival was best 
for patients with a G1 tumor 164,14 months (CI95%: 133,9 – 194,39 months). The G2-group 
reached a mean overall survival of 87,93 months (CI95%: 58,18 – 117,68 months) and the 
G3-group showed the worst mean overall survival of 37,17 months (CI95%: 7,86 – 66,47 
months). Figure 16. 
 
 
Fig. 16 Calculated survival rates illustrating the grading (G).  
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4.5 Lymph node and distant metastases 
In this chapter we analyzed the probability to develop lymph node or distant metastases. We 
found a correlation between tumor size and the rate of lymph node metastases. For these 
calculations only operations were considered within which lymph nodes were sampled. 
Therefore we analyzed the files of 54 patients. 
 
4.5.1 Correlation of tumor size and lymph node metastases 
We found a correlation between tumor size and the probability of positive lymph nodes. One 
patient (8,33 %) with a T1 tumor had positive lymph nodes and four (28,57 %) with a T2 
tumor. This rate increases if there was a T3 or T4 tumor found. Nine patients (36 %) with a 
T3 tumor and four patients (66,67 %) with a T4 had lymph node metastases. The increase is 
obvious from group to group, however only the difference between T1 and T4 is statistically 
significant. Figure 17 
 
 
Fig. 17 Correlation of tumor size and the probability of lymph node metastases. (* p<0,05) 
 
  
T1 T2 T3 T4
20%
40%
60%
80%
100%
0%
P
at
ie
nt
s 
w
ith
 ly
m
ph
 n
od
e 
m
et
as
ta
se
s
 *
Results 
Florian Bösch  Seite 36 
 
4.5.2 Correlation of tumor size and distant metastases 
There was also an increase in the probability to have distant metastases at the time of 
operation when the primary tumor was bigger. Again only one patient (5,26 %) with a T1 
tumor and only two patients (14,29 %) with a T2 tumor had distant metastases. Seven 
patients (28 %) with a T3 tumor suffered from distant metastases and four (57,14 %) with a 
T4 tumor. The difference from T1 and T2 to T4 was statistically significant. Figure 18 
 
 
Fig. 17 Correlation of tumor size and the probability of distant metastases. (* p<0,05) 
 
 
4.6 ENETS and UICC classification 
After TNM assessment the patients were further subdivided according to the two main 
classification systems, the ENETS and the UICC classification system. For exact 
classification the histopathology has to contain full information on TNM. As mentioned above 
almost the entire medical history of one patient is missing and twelve operations were carried 
out without resecting any lymph nodes and as a consequence classification to either group is 
not feasible in these special cases.  
Therefore we find 54 patients in the ENETS classification system subdivided into one of the 
following groups. In group I are ten patients (18,5%) and in II A are nine patients (16,7 %), 
again in group II B are ten patients (18,5 %). Group III A contains no patient, however, III B 
has eleven patients (20, 4 %) and group IV represents even the largest cohort with 14 
patients (25,9 %).  Figure 18 a 
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Fig. 18 a Distribution according to the ENETS classification system 
 
The UICC group I A contains ten patients (18,5 %) and group I B nine patients (16,7%). The 
groups II A and II B have nine (16,7%) and ten (18,5 %) patients, respectively. Group III 
consists of two patients (3,7 5%) and group IV of 14 patients (25,9 %). Figure 18 b 
 
 
Fig. 18 b Distribution according to the UICC classification system 
 
 
4.7 Survival rates for ENETS and UICC classification system 
The survival rates were calculated for both main classification systems – ENETS and UICC. 
One patient in the entire cohort was lost for follow up, but no lymph nodes were resected in 
this patient. Hence, this patient was not classified into ENETS or UICC classification system. 
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The three patients who died within 30 days are also excluded from this calculation. No lymph 
nodes were resected of one of these three patients and therefore could not be classified to 
one of the groups. 
 
4.7.1 Survival rates for ENETS classification system 
Patients were distributed in almost every group, with exception of group III A. The 3-year 
survival rates of the different groups were as follows. Group I had a 3-year survival rate of 89 
%. Groups II A and IIB reached 78 % and 80 %, respectively. No patient matched in group III 
A, but group III B showed a 3-year survival rate of 80 % as well. The worst result showed 
group IV with a 3-year survival rate of 60 %. The calculated mean overall survival rates of the 
different groups were as follows: Group I had a calculated mean overall survival of 57,5 
months (CI95%: 45,88 – 69,11 months), group II A 98,56 months (CI95%: 72,18 – 124,93 
months), group II B 85,06 months (CI95%: 57,51 – 112,61 months), group III B 149,98 
months (CI95%: 87,21 – 212,76 months) and group IV 48,83 months (CI95%: 29,9 – 67,76 
months). Figure 19. 
 
 
Fig. 19 ENETS classification survival.  
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4.7.2 Survival rates for UICC classification system 
In contrast to the ENETS classification system every group within the UICC classification 
system was occupied. Group I A had the same survival rate than ENETS group I (89 %). 
Furthermore, correlated group I B with ENETS group II A. The survival rate for both groups 
was 78 %. The 3-year survival rates of group II A and II B reached both 78 %. Astonishingly, 
group III had the best survival rate with 100 %, however only two patients fulfilled the criteria 
for this group. Since the requirements for stage IV were the same in both classification 
systems, the 14 patients had the same 3-year survival rate of 60 %. The diverse calculated 
overall survival times of the UICC classification were not as expected. The second worst 
survival time had group I A with 57.5 months (CI95%: 45,88 – 69,11 months), however, 
second best survival rate was reached within group I B with 98,56 months (CI95% 72,18 – 
124,93 months). Since there was no death within group III survival rate was 100 %. The 
difference between II A and II B was also huge. Group II A achieved a calculated survival 
rate of 80,22 months (CI95%: 50,67 – 109,76 months) compared to 146,35 (CI95%: 81,91 – 
210,75 months), which was even the best survival rate. Group IV had the worst survival rate 
with 48,83 months (CI95%: 29,9 – 67,76 months). Figure 20. 
 
 
Fig. 20 UICC classification survival.  
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4.8 Survival rates in regard to surgery 
4.8.1 Operation time 
Firstly the median operation time was calculated, in which the two groups showed an 
equivalent distribution. The median operation time was 192,5 minutes. There was a 
statistically significant difference regarding the survival when the operation time exceeded 
the median operation time. Patients with a shorter operation time had a better survival. In our 
patients the calculated median overall survival was 163,63 months (CI95%: 129,73 – 197,52) 
if the median operation time was not exceeded. This rate decreases to 70,26 months 
(CI95%: 53,8 – 86,73) when the operation took longer than the median duration of 192,5 
minutes (p<0,05). Figure 21. 
 
 
Fig. 21 Survival rate regarding operation time (p<0,05). Green line: exceeding the median operation 
time, blue line: below the median operation time. 
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4.8.2 Type of surgery 
In a next step the two main groups of surgery (pancreatic head resection, distal 
pancreatectomy) were analyzed. The outcome did not differ no matter which type of 
operation was carried out. The calculated median overall survival if a distal pancreatectomy 
was done was 135 months (CI95%: 97,42 – 172,63) compared to otherwise operated 
patients with 83,72 months (CI95%: 67,91 – 99,54) (p=n.s.). Figure 22 a. 
When a pancreatic head resection was performed there was also no significant difference in 
the calculated overall survival rates. Patients undergone a major resection survived 136,5 
months (CI95%: 103,37 – 169,62) compared to 72,52 months treated with a different 
procedure (CI95%: 50,91 – 94,14) (p=n.s.). Figure 22 b. 
 
 
Fig. 22 a Survival rate of distal pancreatectomy (p=n.s.). Green line: distal pancreatectomy, blue line: 
other operation. 
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Fig. 22 b Survival rate of pancreatic head resection (p=n.s.). Green line: pancreatic head resection, 
blue line: other operation.  
 
 
4.9 Univariate analysis of severe complications  
The cohort was analyzed in an univariate approach concerning severe complications 
according to the classification system by Dindo et al. In this publication Dindo and coworkers 
classified complications from grade I to grade V. The grades range from not serious grade I 
complications to death of the patient (grade V) 139.  
In this setting a severe complication was classified as grade III-a or higher. Grade III 
complications are defined as complications requiring surgical, endoscopic or radiologic 
intervention without (III-a) or with (III-b) general anesthesia. In this calculation the entire 
cohort was included since the direct postoperative morbidity is known for every patient.   
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4.9.1 Severe complications and operation time 
Firstly, the operation time as a risk factor for severe complications was analyzed. In the 
univariate analysis the operation time was no significant risk factor. Nonetheless, there was 
trend as the one-sided chi-square test was statistically significant. Figure 23 
 
 
Fig. 23 Univariate analysis of the operation time and severe complications (p=n.s.) 
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4.9.2 Severe complications and age 
The question was, if the age of the patient is a risk factor to develop a severe complication. 
In our cohort there was no significant correlation of age and severe complications. (p=n.s.) 
Figure 24 
 
 
Fig. 24 Univariate analysis of the age and severe complications (p=n.s.) 
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4.9.3 Severe complications and gender 
In the next analysis the influence of the gender of a patient on severe complications was 
examined. There was no significant difference between female and male patients. (p=n.s.) 
Figure 25 
 
 
Fig. 25 Univariate analysis of the gender and severe complications (p=n.s.) 
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4.9.4 Severe complications and pancreatic head resection 
The type of surgery was also topic of the univariate analysis. There were not more severe 
complications when a pancreatic head resection was performed. The one-sided chi-square 
test was significant suggesting a tendency to more complications when a more extensive 
resection was carried out. (p=n.s.) Figure 26 
 
 
Fig. 26 Univariate analysis of pancreatic head resections and severe complications (p=n.s.) 
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4.9.5 Severe complications and distal pancreatectomy 
Similar to pancreatic head resections there was no statistically significant difference of the 
number of severe complications when a distal pancreatectomy was performed. Furthermore, 
there was no trend towards a higher rate of complications since this was the less extensive 
procedure. (p=n.s.) Figure 27 
 
 
Fig. 27 Univariate analysis of distal pancreatectomy and severe complications (p=n.s.) 
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4.9.6 Severe complications and the resection margin 
The histopathology reports were next to be analyzed. First issue was to examine the impact 
of the resection margin on the appearance of severe complications. The univariate analysis 
showed no influence of tumor free resection margins on the frequency of severe 
complications. (p=n.s.) Figure 28 
 
 
Fig. 28 Univariate analysis of the resection margin and severe complications (p=n.s.) 
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4.9.7 Severe complications and metastases 
Another question to be answered was if the presence of distant metastases had an influence 
on the morbidity in our cohort. There was no significant difference if the patients suffered of 
distant metastases or not. (p=n.s.) Figure 29 
 
 
Fig. 29 Univariate analysis of the presence of metastases and severe complications (p=n.s.) 
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4.9.8 Severe complications and lymph nodes 
The last issue to be analyzed was the impact of positive lymph nodes on the appearance of 
severe complications. Again there was no statistically significant difference in the frequency 
of severe complications no matter if there were negative or positive lymph nodes resected. 
(p=n.s.) Figure 30 
 
 
Fig. 30 Univariate analysis of negative or positive lymph nodes and severe complications (p=n.s.) 
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4.10 Univariate analysis of re-operations 
As mentioned above, six patients (9,1 %) required at least one re-operation due to a 
complication. Therefore, risk factors for re-operations were evaluated in an univariate way. 
 
4.10.1 Re-operation and operation time 
In the first analysis the probability to be re-operated in regard to the operation time was 
investigated. The operation time seems to correlate with complications, however, this finding 
was not statistically significant. The rate of re-operations in turn was more frequent in the 
group of patients with longer primary operation times. This difference was statistically 
significant. (p<0,05) Figure 31 
 
 
Fig. 31 Univariate analysis of operation time and the probability of re-operation (p<0,05) 
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4.10.2 Re-operation and age 
Secondly the influence of the patient’s age on the rate of re-operations was tested. The 
univariate Chi-square test showed that there is no statistically significant influence of the 
patient’s age. (p=n.s.) Figure 32 
 
 
Fig. 32 Univariate analysis of age and the probability of re-operation (p=n.s.) 
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4.10.3 Re-operation and pancreatic head resection 
The different surgical approaches were investigated next. Again only the two most common 
resection strategies (pancreatic head resection and distal pancreatectomy) were explored.  
Patients who underwent a pancreatic head resection did not have a higher risk of a re-
operation. (p=n.s.) Figure 33 
 
 
Fig. 33 Univariate analysis of pancreatic head resection and the probability of re-operation (p=n.s.) 
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4.10.4 Re-operation and distal pancreatectomy 
Lastly the group of distal pancreatectomies was topic of the univariate analysis. Comparable 
to the group of pancreatic head resections the distal pancreatectomy group did not show a 
higher rate of re-operations. (p=n.s.) Figure 34 
 
 
Fig. 34 Univariate analysis of distal pancreatectomy and the probability of re-operation (p=n.s.) 
 
 
4.11 Multivariate analysis of risk factors for survival 
After univariate analyses independent risk factors for survival had to be identified. Therefore 
risk factors, which showed a p-value <0,20 in Fisher’s t-test in the univariate analysis, were 
further studied in a multivariate analysis. Variables, which fulfilled these criteria, were m-
status, r-status, g-status, operation time and pancreatic head resection. 
Cox multivariate regression analysis showed that the presence of distant metastases at the 
time of operation was an independent risk factor. This was the most powerful factor to 
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influence overall survival with a Hazard ratio of 4,72 (CI95%: 1,95 – 11,39). Furthermore, the 
grading of the tumor and the resection margins could also be identified as significant 
prognostic relevant. Nonetheless, the duration of the operation and a pancreatic head 
resection were no independent risk factors. Figure 35 
 
 
Fig. 35 Cox multivariate regression analysis of independent risk factors for survival 
 
 
4.12 Multivariate analysis of the risk of severe complications 
Subsequently, a multivariate analysis of risk factors for severe complications was conducted 
to test risk factors of the univariate analysis. Again only risk factors with a p-value <0,20 in 
Fisher’s t-test were considered, therefore, operation time and the type of surgery (pancreatic 
head resection or distal pancreatectomy) were evaluated. 
In the multivariate analysis no independent risk factor for the incidence of severe 
complications could be identified. Figure 35 
 
 
Fig. 36 Multivariate analysis of independent risk factors for the incidence of severe complications 
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4.13 Multivariate analysis of risk factors for re-operation 
Only one statistically significant risk factor for the probability of a re-operation could be 
identified in the univariate analysis. This single risk factor was the operation time. For the 
multivariate analysis again all risk factors which had a p-value <0,20 in Fisher’s t-test were 
analyzed. Hence, the operation time, if a pancreatic head resection was carried out and the 
age of the patient were studied.  
The multivariate analysis confirmed the duration of the operation as an independent risk 
factor for the rate of re-operations. The longer the primary operation took, the more probable 
was a subsequent re-operation in the analyzed cohort. The risk to get re-operated was 
increased 9,48 times in this case (CI95%: 1,05 – 85,51; p<0,05). The remaining two 
analyzed variables (median age, pancreatic head resection) were statistically not significant 
in the multivariate setting. Figure 37 
 
 
Fig. 37 Multivariate analysis of independent risk factors for the probability of a re-operation 
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5 Discussion 
Neuroendocrine tumors are rare neoplasm but the incidence is increasing 11. Over the last 
years different therapy strategies were evaluated. Nonetheless, surgery is still the gold 
standard if applicable since the only chance of cure is complete tumor resection 140, 141. It is 
universally accepted to perform surgery in a metastasized setting, either to alleviate 
symptoms due to a functional pNET or to reduce the tumor burden. Patients benefit most if 
the primary tumor and the metastases are resected similarly 142. Resection and/or RFA of 
liver metastases could improve 5-year survival from 25% up to 72% compared to patients 
whose liver metastases were treated not surgical 143. 
Since resection of the tumor is the only chance of cure and pNETs show a low proliferation 
rate, more aggressive approaches are feasible when compared to adenocarcinoma of the 
pancreas. pNETs are slow growing tumors and therefore survival rates are good even for 
metastasized tumors. To control hepatic metastases systemic therapy or liver directed 
therapies like TACE or selective internal radiation therapy (SIRT) are well-established 
procedures. Hence, a multidisciplinary approach leads to satisfactory survival rates.  
 
 
5.1 Reflecting the “official” line regarding various risk factors 
The introduction of the ENETS guidelines in 2006 and with it the implementation of the 
proliferation marker Ki-67 was very useful to optimize the individual therapy 4, 5. Therefore we 
favor the ENETS TNM staging. Different publications demonstrated inferior survival rates for 
patients with G3 tumors 144, 145, hence, G3 tumors were underrepresented in our cohort (n=6, 
9,1 %). According to the literature the outcome of the analyzed patients differed depending 
on whether a patient suffered of a G1 or G2 or G3 tumor. We showed a 5-year survival rate 
of 75 % (G1) vs. 63 % (G2) vs. 16 % (G3). These findings were in direct correlation with 
international publications on this topic and G3 pNETs should be regarded as different tumors 
than G1 pNETs. The differences between G1 and G2 were not huge and within the first three 
years almost the same.  
An important point of criticism of the ENETS classification system is the prognostic value of 
the grading system. Currently a tumor is classified as G1 when Ki-67 index is below 2 %, G2 
tumors have a Ki-67 index of 2 – 20 % and tumors with higher Ki-67 levels are classified as 
G3 tumors with the worst prognosis. Scarpa et al. propagate a modification of the cut-off 
levels of Ki-67 index for the three groups. In their study with more than 250 patients suffering 
of pNET they introduced their modified tumor grading with cut-offs at 5 and 20 %, which 
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showed to be prognostic relevant 87. Unfortunately, we do not have a Ki-67 
immunohistochemistry of every specimen and therefore we could not verify these findings. 
Nonetheless, we set off a prospective study including every type of gastroenteropancreatic 
neuroendocrine tumor, which among other things will focus on different cut-off levels of Ki-67 
index.  
Internationally there is almost no doubt about the benefit of the Ki-67 index, however, there 
are contradictory reports on other risk factors.  
An obstacle to prove a particular variable as an independent risk factor is often complicated 
due to the fact that analyzed groups are small. In our cohort with 66 patients we could not 
demonstrate if either UICC or ENETS classification system is prognostic relevant, however, 
this is one of the bigger single center cohorts. The median overall survival of the different 
groups was scattered widely and no conclusion could be drawn out of these two 
classification systems. Nonetheless, we were able to state that group IV had the worst 
overall survival, however, there was no significant difference within the other groups (Figure 
38). This is most likely because of the few patients in every group. Hence, this should not 
lead to the misinterpretation that either classification is inapplicable and these findings are 
concordant to other publications 84.  
However, there are also studies, which show a correlation of survival rates and classification 
systems 144, 146. Sellner et al. saw a prognostic relevance of TNM categories in their 
investigated population. Not unexpected showed group IV the worst outcome. The median 
follow up time was 57 months (2 – 240 months) and only 18 patients were analyzed 144. 
Therefore, the main problem of the practicability of both classification systems is the plethora 
of different groups in combination with too little patients investigated in a single study. 
 
GROUP A B C 
I 57,495 45,876 69,114 
IIA 98,556 72,182 124,929 
IIB 85,057 57,505 112,609 
IIIB 149,983 87,21 212,757 
IV 48,827 29,896 67,758 
 
Fig. 38 Calculated median overall survival (months) of the ENETS classification system (group I – IV). 
A: calculated median overall survival. B: CI95% minimum. C: CI 95% maximum. 
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5.2 Size does matter 
Another important issue, which is internationally discussed controversially, is the surgical 
approach concomitant with the oncologic radicalness. As mentioned above Ki-67 index is an 
independent risk factor and determines in a way the surgical approach. An enucleation of an 
insulinoma is not even widely accepted, the organ sparing procedure is demanded. However, 
the discrepant positions are obvious when the eligible surgical radicalness should be 
determined for tumors of 2 – 4 centimeters. If Ki-67 index is known the discrepancy shrinks.   
Concordant to many other studies we could show that tumor size is not an independent 
prognostic factor (Figure 9). However, we saw that tumor size influences the probability of 
lymph node metastases. The chance of positive lymph nodes correlated with the size of the 
resected tumor. Patients with a T4 tumor had in 66,67 % lymph node metastases, but, T1 
tumors had only a risk of 8,33 % of positive lymph nodes (p<0,05). Enucleations were 
excluded in this calculation since no lymph nodes were resected via this approach.  
Nonetheless, we demonstrated that lymph node metastases did not influence the overall 
survival (Figure 10). This point is discussed very controversially with a majority sympathizing 
with our views 84, 109, 141, 144, 147. Bilimoria et al. who analyzed over 3500 patients with pNET 
lymph node metastases were a significant prognostic factor on univariate analysis, but not on 
multivariate analysis 148. Therefore, an aggressive surgical strategy should be considered in 
patients with tumors > 2 cm.  
Furthermore, an aggressive surgical approach in patients with tumors > 2 cm is confirmed by 
the fact that tumor size correlates with the presence of distant metastases. We have seen 
distant metastases in 5,26 % in patients with T1 tumors and this rate increases almost 
threefold if a patient suffers of a T2 tumor (15,29 %). Most distant metastases were seen in 
patients with T4 tumors (57,14 %).  
Casadei and coworkers showed in a study that enucleation can be performed safely in 
patients with tumors up to 4 cm. Their analysis included 46 patients of which 15 underwent 
enucleation and there was no difference in the overall survival. The title of the study might be 
misleading since the mean tumor size was 1,9 cm (+/- 0,8) in the enucleation group. 
Enucleation was more frequently used in patients with functioning tumors 149.  
When enucleation is performed a proper lymphadenectomy is not usually done. This is in fact 
no disadvantage for the patients because most enucleated tumors are benign functioning 
tumors like insulinomas or smaller than 2 cm. However, we could demonstrate that the rate 
of distant metastases is higher in patients who also have lymph node metastases. Patients 
with positive lymph nodes showed in 38,89 % distant metastases, whereas N0 patients 
suffered in 19,44 % of distant metastases.  
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The presence of distant metastases is an independent prognostic factor for the overall 
survival in our group. A Hazard ratio of 4,72 (CI95%: 1,95 – 11,39) was seen in patients with 
metastases, which led to a 472 % greater risk to decease earlier (p<0,05) (Figure 34). 
Hence, an enucleation of a tumor exceeding 2 cm should be performed only if a complete 
preoperative workup was done and Ki-67 index should be known. Moreover, the higher 
probability of lymph node metastases associated with pNETs bigger than 2 cm carries the 
risk of recurrent disease if no lymph nodes were resected.  
 
 
5.3 Prognostic relevance 
As mentioned above there are several factors influencing overall survival. Tumor size and 
lymph node metastases were two examples to illustrate dissent in international publications. 
One of the main problems might be the lack of statistical power of many studies. pNETs are 
a rare entity, hence single center experiences are not always including a lot of patients. 
There are publications with only 18 or 22 patients but even postulating significant findings 144, 
150. Another problem are the differences within the study population in regard to treatment 
and follow up periods vary significantly between studies. 
However, we presented the presence of distant metastases as an independent risk factor 
(Figure 34). Although, there are several publications in which distant metastases were not of 
prognostic relevance 84, 109, but, the majority supports our hypothesis 83, 146, 151. The median 
survival of a patient with distant metastases was 48,83 months (CI95%: 29,9 – 67,76 
months) compared to 150,23 months (CI95%: 120,08 – 180,39 months) in patients without 
metastases (p<0,05). Nonetheless, stage IV patients benefit from an aggressive surgical 
approach compared to those not operated 152, 153. In regard to pNETs the indicator of 
advanced malignancy, like lymph node or liver metastases, should be re-evaluated. Hence, 
patients with liver metastases should be considered for surgery as well.  
There are also divergent positions on the influence of tumor free resection margins. 
Proponents of the unimportance of tumor free resection margins may argue that this rate is 
anyway overestimated, since there is evidence that standardization of histologic screening 
increases that rate of tumor infiltrated resection margins after pancreatic surgery 154. It is not 
remarkable that investigators do not ascribe importance to resection margins when even 
debulking operations lead to a survival benefit. Nonetheless, there are different findings as 
well 141 and in our study local tumor control was also an independent risk factor. Cox 
multivariate regression analysis revealed the resection margin as prognostic relevant with a 
median survival rate of 152,07 months (CI95 %: 123,74 – 180,4 months) in patients with 
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tumor free resection margins (Figure 34). Patients with a R1 situation had a median survival 
rate of 51,65 months (CI95%: 28,09 – 75,2 months) (p<0,05).  
We analyzed further variables for their prognostic relevance for the overall survival. Sex and 
age of the patient or the surgical approach (pancreatic head resection or distal 
pancreatectomy) were no independent risk factors. These findings are concordant to other 
publications. Nonetheless, working groups published unique relevant prognostic factors like 
location of the tumor 145 or functional status of the tumor 155 or association of MEN-1 151. In 
accordance with this “tradition” we introduce the operation time as a risk factor (Figure 20). In 
our patients the calculated median overall survival was 163,63 months (CI95%: 129,73 – 
197,52 months) if the median operation time was not exceeded. This rate decreased to 70,26 
months (CI95%: 53,8 – 86,73 months) when the operation took longer than the median 
duration of 192,5 minutes (p<0,05). However, this effect was only statistically significant in 
univariate analysis. 
 
 
5.4 Morbidity and mortality 
The overall complication rate in our series came to 30,77 %. This rate is concordant to other 
studies and ranges in the middle of published results. Furthermore, the rates of 30-day 
mortality and of re-operations were comparable to international study groups 84, 109, 145.  
The multivariate analysis did not revealed any risk factor for the occurrence of a 
complication. Analysis included operation time, sex, age of patients, surgical strategy and 
TNM (Figure 35). Pancreatic fistula was seen in 13 patients (19,7 %) and five patients 
required an interventional drainage (ISGPS B). A possible explanation of pancreatic fistulas 
might be that the pancreas of a patient with pNET is generally soft, making the anastomosis 
challenging. We have seen three patients with an insufficiency of the 
pancreaticojejunostomy, one requiring re-operation. Unfortunately this patient died due to 
postoperative complications.  
In total we have lost three patients within 30 days, whereby one patient died because of a 
heart failure but two deaths were directly related to surgery. Hence, our 30-day mortality rate 
was 4,5 %.  
Six patients (9,1 %) of the investigated cohort had to be re-operated because of a specific 
complication. All re-operations were necessary due to anastomotic leakage and insufficiency 
of the hepaticojejunostomy was in four cases the indication for the re-operation. Neither the 
surgical strategy (pancreatic head resection or distal pancreatectomy) nor the age of the 
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patient did influence the probability of re-operations. However, in the multivariate analysis the 
duration of the primary operation was an independent risk factor to get re-operated (Figure 
36) (p<0,05).  
Therefore, we suggest that pancreatic resection for pNETs is safe but surgery should be 
performed in a high-volume center. Treatment of pNETs should always be multi-disciplinary 
due to the rarity and different manifestations of the disease. A primarily palliative setting may 
be converted with liver directed therapy or systemic treatment to a resectable tumor burden. 
Moreover, an answer to the controversial discussion of risk factors is only possible with a 
large study population to gain statistical power. High-volume centers can initiate clinical trials 
in cooperation either with other centers and/or with the various medical departments involved 
in the treatment of pNETs. 
 
 
5.5 Limitations 
We could present a study of 66 consecutive patients with pNETs who all underwent tumor 
resection. Nonetheless, this is a heterogenic population including functional active and 
inactive as well as benign and malignant tumors. Within the 15 years of recruiting the 
understanding of this tumor entity has changed and surgical techniques along with treatment 
strategies have improved. We have included only patients whose tumor was resected which 
in turn led to a bias. Furthermore, the follow up period started with the date of the operation. 
We did not take account into the time period between diagnosis and surgery or tumor 
directed therapy previous to surgery. This may have influenced our results and overall 
survival rates negatively. Commonly to almost every study a limitation of our study is its lack 
of statistical power because of a small cohort and impossibility of subgroup analysis therein. 
 
Due to the rarity of pNETs our study population is comparable to other published single 
center experiences. The size of our group is in the upper quarter of published studies. 
Another advantage is the completeness of data with only one patient lost for follow up. We 
analyzed only patients whose primary tumor was resected, hence we have a very uniform 
population. Moreover, we could verify already published results and even present new 
relevant factors in multivariate analyses. Nevertheless, there have studies been published in 
which only univariate analyses were performed.  
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6 Abstract 
Introduction.  
Neuroendocrine tumors of the pancreas (pNET) are rare neoplasms, although the incidence 
is rising. pNETs may get symptomatic due to secreted peptides (diarrhea, hypoglycemia) or 
may be functionally inactive. Aim of this study was to assess morbidity and mortality and to 
discover risk factors of all resected pNETs at our institute.  
Methods.  
With a retrospective analysis we studied the data of patients who got operated because of a 
pNET from 1996 to 2011. One inclusion criterion was that the primary tumor has to be 
resected, therefore we have no patients included who had undergone only a explorative 
laparotomy. Minimal follow up time was 12 months. Besides demographic data we also 
evaluated prognostic relevant parameters for morbidity, mortality and overall survival.  
Results. 
From 1996 to 2011 66 patients (33 female, 33 male) were operated because of a pNET. A 
distal pancreatectomy was done commonest (n=30), followed by 22 pancreatic head 
resections. Pancreatectomy had to be done in 5 patients and a segmental resection was 
feasible in 9 patients. The majority of patients had a G1 or G2 tumor (n=60, 90,91 %) and 14 
patients (21,21 %) suffered from distant metastases at the time of operation. We could 
demonstrate that the grading, the presence of metastases and the resection margins had a 
significant influence on the overall survival. However, lymph node metastases, the surgical 
approach or the operation time did not have prognostic relevance. Pancreatic fistula was 
seen in 13 patients (19,7 %) and five patients required an interventional drainage (ISGPS B). 
An insufficiency of the pancreaticojejunostomy was detected in 3 patients. Six patients (9,1 
%) had to be re-operated due to a complication. The multivariate analysis did not reveal any 
risk factor to develop a complication. However, we could demonstrate that the duration of the 
primary operation had a significant influence on the rate of re-operations. The calculated 
mean overall survival was 130,17 months (CI95%: 103,21 – 157,14 months) with a 
calculated 5-year survival of 66 %. The 30-day mortality was 4,5 % (n=3). 
Discussion. 
International working groups are divided on risk factors, however, we could demonstrate that 
metastases, grading and resection margins significantly influence survival. These findings 
are mainly concordant with the majority of other publications. Due to the rarity of these 
tumors treatment should be done in a center in a multidisciplinary setting and surgery can be 
done with an acceptable morbidity and mortality.  
Abstract 
Florian Bösch  Seite LLL 
 
7 Zusammenfassung 
Einleitung. 
Neuroendokrine Tumore des Pankreas (pNET) sind seltene Tumore, wenngleich ihre 
Inzidenz steigt. pNETs können symptomatisch werden wenn sie Peptide sezernieren 
(Diarrhoe, Hypoglykämie) oder sie bleiben funktionell inaktiv. Ziel dieser Studie war es, die 
Morbidität, Mortalität und Risikofaktoren hierfür aller an unserem Zentrum operierten 
Patienten mit einem pNET zu erfassen. 
Material und Methoden. 
In einer retrospektiven Analyse haben wir alle Daten von Patienten, die aufgrund eines pNET 
zwischen 1996 und 2011 operiert wurden, ausgewertet. Es sind in dieser Studie nur 
Patienten deren Tumor reseziert wurden enthalten, das heißt Patienten, die eine explorative 
Laparotomie erhalten haben, sind exkludiert. Die minimale Nachverfolgungszeit beträgt 12 
Monate. Neben demographischen Daten wurden auch prognostisch relevante Parameter für 
Morbidität, Mortalität und das Gesamtüberleben evaluiert.  
Resultate 
Zwischen 1996 und 2011 wurden 66 Patienten (33 weibliche, 33 männliche) mit einem pNET 
operiert. Eine Pankreaslinksresektion war die häufigste Operation (n=30), gefolgt von einer 
Pankreaskopfresektion (n=22). Eine Pankreatektomie wurde bei fünf Patienten und eine 
segmentale Resektion bei neun Patienten durchgeführt. Der Großteil der Patienten hatte 
zum Operationszeitpunkt einen G1 oder G2 Tumor (n=60; 90,91 %), 14 Patienten (21,21 %) 
einen G3 Tumor. Wir konnten zeigen, dass das Tumorgrading, das Vorhandensein von 
Fernmetastasen und das Erreichen einer R0-Resektion einen signifikanten Einfluss auf das 
Gesamtüberleben haben. Lymphknotenmetastasen, die Resektionsstrategie oder die 
Operationszeit hatten jedoch keine prognostische Relevanz. Eine Pankreasfistel trat bei 13 
Patienten (19,7 %) auf und fünf Patienten benötigten eine interventionelle Drainage (ISGPS 
B). Eine Insuffizienz der Pankreatikojejunostomie erlitten drei Patienten.  Sechs Patienten 
mussten (9,1 %) aufgrund einer Komplikation revidiert werden. In der multivariaten Analyse 
konnte kein Risikofaktor für das Auftreten postoperativer Komplikationen ermittelt werden. 
Die Dauer der primären Operation hatte allerdings einen direkten Einfluss auf die Rate der 
Revisionen. Das kalkulierte mediane Überleben betrug 130,17 Monate (CI95%: 103,21 – 
157,14 Monate) mit einem kalkulierten 5-Jahres Überleben von 66 %. Die 30-Tages 
Mortalität beläuft sich auf 4,5 % (n=3). 
Diskussion. 
Die internationalen Publikationen sind widersprüchlich in Bezug auf die Risikofaktoren. Wir 
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konnten jedoch darlegen, dass Fernmetastasen, das Grading sowie eine R0-Situtation das 
Überleben signifikant beeinflussen. Trotz der Widersprüche decken sich unsere 
Beobachtungen mit dem Großteil der publizierten Studien. Aufgrund der Seltenheit dieser 
Tumorentität sollte eine Behandlung in einem Zentrum mit einem interdisziplinären Ansatz 
erfolgen. Auch ausgedehnte Resektionen können mit vertretbarer Morbidität und Mortalität 
durchgeführt werden.  
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9 Eidesstattliche Versicherung 
Ich erkläre hiermit an Eides statt, dass ich die vorliegende Dissertation mit dem Thema  
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